Combination Immunotherapy

Mechanism

Related News

TIL therapy shows durable responses in refractory melanoma as adoption expands

May 13, 2026

Tumour-infiltrating lymphocyte therapy has shown durable responses in refractory melanoma, including a 31.4% objective response rate in phase II data. The 2024 FDA approval of Lifileucel marked a milestone as regulators in other markets continue reviews.

Coya Therapeutics Advances ALS Combo Immunotherapy Into Phase 2 Trial

Mar 04, 2026

Coya Therapeutics detailed plans for a Phase 2 trial of combination immunotherapy targeting neuroinflammation in ALS, following a four-patient study showing biomarker improvements and reported slowing of disease progression.